Catalyst
Slingshot members are tracking this event:
Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
CMRX |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 28, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Suppress, Brincidofovir, Hct, Primary Endpoint, Gvhd, Top-line, Results, Phase 3